Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.
about
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit allTherapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapyCYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, HaitiAmprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individualsPharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.Human immunodeficiency virus therapeutics and pharmacogenomicsGenome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphismPharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz.A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study.Modeling and simulation of adherence: approaches and applications in therapeutics.Advances in human immunodeficiency virus therapeutics.The clinical implications of antiretroviral pharmacogenomics.Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.Sex differences in pharmacokinetics and toxicity of antiretroviral therapy.A review of nelfinavir for the treatment of HIV infection.Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDSGenome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variantsEfavirenz: a review."One pill, once daily": what clinicians need to know about Atriplatrade mark.Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIVADME pathway approach for pharmacogenetic studies of anti-HIV therapy.Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.Adverse effects of highly active antiretroviral therapy in developing countries.The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African childrenIn vitro-in vivo correlation of efavirenz tablets using GastroPlus®Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine.Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.Considerations for the antiretroviral management of women in 2008.The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosisA novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus.Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.Pharmacokinetics of Efavirenz at a High Dose of 25 Milligrams per Kilogram per Day in Children 2 to 3 Years Old.Mixed-Effects Models with Skewed Distributions for Time-Varying Decay Rate in HIV Dynamics.Impact of pharmacogenetics on CNS side effects related to efavirenz.Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.
P2860
Q24609011-EA4A7737-7EDA-434A-9033-7FE926DAE0C2Q28539806-82809749-B750-468A-899B-8B60B18F0D76Q30438405-EE683BC5-50E6-48F8-97A5-29C721AC4737Q33938221-6465048B-E64F-4BB3-B725-184A687764CDQ35018246-BFEC95DD-7284-4316-BE37-59F715269697Q35073490-AF3FCDCC-2F4E-4857-BD12-370912FE58B6Q35288691-F078A1E8-CAF0-48BC-AC6F-875680DE01DEQ35364120-9DC02E0D-E76E-4DD2-975E-4530755448A6Q35827416-F09B9C58-BA90-4446-B7C3-92A1E6D2E4A0Q35846143-22CC46B2-2D83-4790-8EDF-994C2484AF60Q36062320-E7C976D9-1857-4A85-A03C-0700FCDD2AFEQ36263781-58BB669D-3671-4AD7-A9D3-0075B06DEEF5Q36341606-2E3DE674-94F6-40DD-A378-D5A5D2FCE747Q36427662-FF4E5303-86D6-48D1-B147-F696B7D95820Q36497078-7BE4BDB8-641F-416D-9566-98FAB76F14F2Q36544977-E393ACB7-5598-4D7B-89D3-1BF5E608B52AQ36546272-F7112F69-81D0-4E00-97FA-CC8285DA6492Q36546278-500152FE-E744-432B-BDEB-FCBC1A3D6372Q36708715-BBE2466F-125F-4BBE-B4B8-73FE291E93AFQ36734592-658AD823-FF9E-4466-AB92-0F7519BD2F94Q36787311-E0107B2B-1B86-465F-938A-836877D4B3D7Q36823570-CDEC780F-D9D5-4C57-89B5-B7F430AF8645Q36840809-817E2AB1-6AA4-4349-BBDE-48405336AB5AQ36845126-DED93627-3BBF-4E5C-907B-B0C19D68910AQ36877237-CF3660D6-072D-4646-AB05-C532176CA244Q36945761-90C33158-9F46-40B1-A9D2-D6EA0FD7DE8EQ37030715-EA06787F-B370-4976-837E-C25725EEF55BQ37126427-0B64F34E-5B81-447D-9BB3-14F0E37EB465Q37204170-D9A0778F-F7E4-4118-AC28-B9663492DB36Q37237006-D4EFE438-8981-4648-9608-1546E87A499FQ37247762-91604926-4D48-4E0F-B19F-85EB76E0BF2EQ37346125-A3AAA9F9-1AA2-4808-8051-6DAE5A599C68Q37466856-BFE86946-1945-4B9F-8009-D16ACEB922CDQ37471061-B1ADF830-2C9E-42B5-B59B-853561D272B0Q37489345-2D095FFA-A6F0-476E-821D-0A86711B9223Q37544540-24D7694A-2CE5-495D-AE27-49C8E25FC099Q38377051-4D8011A9-A0D1-4679-9C82-046B726597E6Q38601241-579B81EF-D6B3-4E78-BF48-9DD665F0C618Q39383647-788AA154-A2F7-4124-AD25-8A833690A15EQ40050910-18DF359D-0BF6-4C79-807A-ED09BB3CDC1C
P2860
Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Population pharmacokinetics an ...... linical Trial Group Study 398.
@ast
Population pharmacokinetics an ...... linical Trial Group Study 398.
@en
Population pharmacokinetics an ...... linical Trial Group Study 398.
@nl
type
label
Population pharmacokinetics an ...... linical Trial Group Study 398.
@ast
Population pharmacokinetics an ...... linical Trial Group Study 398.
@en
Population pharmacokinetics an ...... linical Trial Group Study 398.
@nl
prefLabel
Population pharmacokinetics an ...... linical Trial Group Study 398.
@ast
Population pharmacokinetics an ...... linical Trial Group Study 398.
@en
Population pharmacokinetics an ...... linical Trial Group Study 398.
@nl
P2093
P2860
P1476
Population pharmacokinetics an ...... linical Trial Group Study 398.
@en
P2093
Adult AIDS Clinical Trial Group Study 398
John Mellors
Kara K Bennett
Lewis B Sheiner
Line Labbé
Marc Pfister
Scott M Hammer
Susan Rosenkranz
P2860
P304
P356
10.1128/AAC.47.1.130-137.2003
P407
P577
2003-01-01T00:00:00Z